Cargando…
Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan
IMPORTANCE: The association between sodium-glucose transport protein 2 inhibitor (SGLT2i) use and the incidence of acute kidney injury (AKI) remains controversial. The benefits of SGLT2i use in patients to reduce AKI requiring dialysis (AKI-D) and concomitant diseases with AKI as well as improve AKI...
Autores principales: | Chung, Mu-Chi, Hung, Peir-Haur, Hsiao, Po-Jen, Wu, Laing-You, Chang, Chao-Hsiang, Hsiao, Kai-Yu, Wu, Ming-Ju, Shieh, Jeng-Jer, Huang, Yu-Chuen, Chung, Chi-Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947724/ https://www.ncbi.nlm.nih.gov/pubmed/36811856 http://dx.doi.org/10.1001/jamanetworkopen.2023.0453 |
Ejemplares similares
-
Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan
por: Chung, Mu-Chi, et al.
Publicado: (2021) -
Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
por: Chung, Mu-Chi, et al.
Publicado: (2022) -
Is combined peritoneal dialysis and hemodialysis redundant? A nationwide study from Taiwan
por: Chung, Mu-Chi, et al.
Publicado: (2020) -
Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan
por: Hung, Peir‐Haur, et al.
Publicado: (2021) -
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
por: Su, Yu-Chen, et al.
Publicado: (2022)